How to Get Vyleesi in Arizona: Prescriptions, Telehealth, and Pharmacy Options

What Is Bremelanotide and Why Does It Require a Prescription?

Bremelanotide is a synthetic cyclic heptapeptide that acts on melanocortin-3 and melanocortin-4 receptors in the central nervous system to increase sexual desire [1]. The FDA granted approval on June 21, 2019, making Vyleesi the second approved pharmacotherapy for HSDD in premenopausal women, following flibanserin (Addyi) in 2015 [2]. Because it acts centrally and carries specific contraindications, including co-administration with naltrexone-containing products and patients with uncontrolled hypertension, federal law classifies it as a Schedule-exempt prescription drug requiring licensed prescriber oversight [3].

The drug is dosed as needed, not daily. A woman self-injects 1.75 mg subcutaneously into the abdomen or thigh approximately 45 minutes before anticipated sexual activity and uses no more than one dose every 24 hours [4]. This on-demand profile distinguishes it mechanistically and practically from flibanserin, which requires nightly dosing [5].

Arizona law mirrors federal law on Schedule-exempt prescription drugs. A valid prescriber-patient relationship, documented history, and informed consent are required before any Arizona pharmacy can dispense bremelanotide [6]. The Arizona Medical Board, Arizona Board of Osteopathic Examiners, Arizona State Board of Nursing (for nurse practitioners), and Arizona Regulatory Board of Physician Assistants all recognize telehealth encounters as a sufficient basis for that relationship under Arizona Revised Statutes § 36-3601 [7].

Clinical Evidence Supporting Vyleesi Prescribing in Arizona

The RECONNECT program consisted of two randomized, double-blind, placebo-controlled Phase 3 trials (Study 301 and Study 302) published in Obstetrics and Gynecology in 2019, with a combined enrolled population of 1,247 premenopausal women with HSDD [8]. The primary endpoints were change from baseline in the Female Sexual Function Index (FSFI) desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13.

Across both trials, bremelanotide produced a statistically significant improvement in the FSFI desire domain score versus placebo (P<0.001) and a significant reduction in FSDS-DAO Item 13 (P<0.001) [8]. Roughly 25% of women receiving bremelanotide were classified as responders on the FSFI desire endpoint compared with approximately 17% on placebo [9]. Nausea was the most common adverse event, occurring in 40% of the bremelanotide group versus 1% in the placebo group, though it was generally transient and resolved within 12 hours [8].

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states: "We recommend bremelanotide as an option for premenopausal women who have generalized, acquired HSDD and for whom low sexual desire causes personal distress" [10]. The International Society for the Study of Women's Sexual Health (ISSWSH) echoes this position in its 2022 consensus statement on HSDD management, specifying that bremelanotide should be preceded by a biopsychosocial evaluation to rule out contributory conditions such as thyroid dysfunction, depression, or relationship discord [11].

A 52-week open-label extension of RECONNECT confirmed that women who continued bremelanotide maintained their FSFI desire score improvements without emergent new safety signals, and mean systolic blood pressure elevation remained below 2 mmHg at 52 weeks [12]. That blood-pressure finding is relevant to Arizona telehealth prescribers because it supports the feasibility of home blood-pressure monitoring as a screening tool rather than requiring an in-office manometer reading before every prescription renewal [12].

Telehealth Prescribing of Vyleesi in Arizona: What the Law Actually Says

Arizona is one of the most permissive telehealth states in the country. Arizona enacted HB 2454 in 2019, requiring commercial insurers to cover telehealth services at parity with in-person visits, and it joined the Interstate Medical Licensure Compact (IMLC), allowing out-of-state physicians to obtain an Arizona expedited license [13]. Nurse practitioners in Arizona practice under full practice authority under Arizona Revised Statutes § 32-1601, meaning they can independently evaluate, diagnose, and prescribe bremelanotide without physician co-signature [14].

For a telehealth prescription to be valid in Arizona, three elements must be present. First, the prescriber must hold an active Arizona license or a valid IMLC authorization covering Arizona. Second, the encounter must include a synchronous or asynchronous clinical evaluation sufficient to establish a diagnosis of HSDD. Third, the prescriber must document that the patient is premenopausal, that HSDD causes personal distress (typically scored with the FSDS-R or FSDS-DAO), and that contraindications have been reviewed [15].

Arizona's telemedicine statute does not require a prior in-person visit before prescribing. A video or telephone encounter conducted through a HIPAA-compliant platform satisfies the prescriber-patient relationship requirement for Schedule-exempt medications including bremelanotide [7]. Prescribers who use asynchronous (store-and-forward) platforms must ensure the patient questionnaire captures the contraindication checklist required by the FDA Risk Evaluation and Mitigation Strategy (REMS), though bremelanotide does not currently carry a formal REMS program [4].

The HealthRX clinical team uses a structured four-step telehealth intake for Arizona patients seeking bremelanotide. Step 1: a validated HSDD screener (FSDS-DAO Item 13 score of 2 or higher triggers clinical review). Step 2: contraindication clearance, covering current use of naltrexone, uncontrolled hypertension defined as resting systolic above 165 mmHg or diastolic above 100 mmHg, and cardiovascular disease history. Step 3: baseline blood pressure documentation via home monitor or recent medical record (within 90 days). Step 4: prescriber video review with the patient to confirm goals, discuss nausea management (ondansetron 4 mg as needed is commonly co-prescribed), and obtain electronic informed consent. Most Arizona patients complete steps 1 through 3 asynchronously and connect with the prescriber for a 15-minute video call.

Which Prescribers in Arizona Can Write a Vyleesi Prescription?

Any Arizona-licensed prescriber with authority to write Schedule-exempt medications can prescribe bremelanotide. That group includes physicians (MD and DO), nurse practitioners, physician assistants, and certified nurse midwives whose scope includes pharmacotherapy [6]. A prescriber does not need a specialist designation, though gynecologists, sexual medicine specialists, and women's health NPs most commonly encounter HSDD in clinical practice [16].

The North American Menopause Society (NAMS) notes that "all clinicians treating women for sexual health concerns should be familiar with the approved pharmacotherapies, including bremelanotide and flibanserin, and should document a distress criterion before initiating treatment" [17]. That guideline applies equally to primary care providers in Arizona and to telehealth-only platforms serving Arizona ZIP codes.

Physician assistants in Arizona practice under a supervision agreement with a collaborating physician but can independently generate and transmit prescriptions, including for bremelanotide, as long as the supervising physician's information appears on the prescription per Arizona Board rules [18].

Labs and Baseline Assessment Required Before Vyleesi in Arizona

No specific laboratory panel is mandated by the FDA label for bremelanotide [4]. The label requires only that the prescriber confirm the patient is premenopausal and does not have uncontrolled hypertension [4]. However, responsible clinical practice, as outlined in the ISSWSH 2022 process-of-care document, calls for targeted baseline testing to exclude treatable contributors to low desire [11].

The standard HealthRX baseline panel for Arizona patients includes thyroid-stimulating hormone (TSH), free testosterone (total and free), prolactin, estradiol, and a basic metabolic panel if hypertension risk is present. None of these require a clinic visit. Arizona-licensed direct-to-consumer lab companies such as LabCorp and Quest Diagnostics accept provider-ordered draw requisitions electronically, and patients can walk into a draw site within 48 hours of completing their telehealth intake [19]. Results route back to the prescriber portal within 2 to 4 business days.

Blood pressure is the single non-negotiable pre-prescription check. The FDA label states that bremelanotide should not be used in patients with cardiovascular disease or uncontrolled hypertension because transient increases in blood pressure of approximately 2 to 4 mmHg systolic have been observed in the hour following injection [4]. A documented home reading taken on two separate mornings, or a reading from any healthcare encounter within the preceding 90 days, satisfies this requirement for most telehealth prescribers [20].

Arizona Pharmacy Options: Retail, Mail-Order, and 503A Compounding

Brand-name Vyleesi (Palatin Technologies / AMAG): The branded 1.75 mg auto-injector is available at retail pharmacies in Arizona that stock specialty injectables, including Walgreens Specialty Pharmacy, CVS Specialty, and independent specialty pharmacies. Because brand-name Vyleesi carries a list price of approximately $1,050 per single-dose injector, most cash-pay patients find the cost prohibitive without insurance coverage [21].

Insurance coverage in Arizona: Arizona Medicaid (AHCCCS) does not cover bremelanotide as of 2025. Commercial insurers vary. Cigna, UnitedHealthcare, and Aetna Arizona plans may cover Vyleesi with prior authorization, but coverage rates across plans remain below 40% nationally [22]. When coverage is denied, the Palatin patient-assistance program can reduce out-of-pocket costs to under $99 per dose for eligible patients [23].

Prior authorization documentation: Insurers requiring prior authorization typically demand three elements. The prescriber must document a DSM-5-consistent HSDD diagnosis with a validated distress score, confirm premenopausal status with a recent FSH or estradiol result or clinical documentation, and attest that the patient has tried at least one non-pharmacological intervention such as psychotherapy or couples counseling. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 213 specifically supports documenting psychosocial evaluation as a prerequisite when pursuing insurance coverage for HSDD pharmacotherapy [24].

503A compounding in Arizona: Arizona-licensed 503A compounding pharmacies can prepare bremelanotide in alternative formulations for individual patients when a prescriber documents a clinical rationale. The most common rationale is patient inability to self-inject the commercial auto-injector due to needle phobia or dexterity limitations, warranting a different delivery vehicle. Compounded bremelanotide is not FDA-approved and does not carry the same regulatory oversight as the branded product [25]. The FDA's guidance on compounding distinguishes 503A pharmacies (patient-specific, prescription-required) from 503B outsourcing facilities (bulk, without individual patient prescriptions) [25]. Arizona 503A pharmacies operating under Arizona Board of Pharmacy oversight are legally authorized to compound bremelanotide if a valid individual prescription exists and a legitimate medical need is documented [26].

How Long Does It Take to Receive Vyleesi in Arizona?

Standard timelines differ by pharmacy type. A retail specialty pharmacy in a major Arizona metro such as Phoenix, Tucson, or Scottsdale can have the branded auto-injector ready within 1 to 3 business days of prescription receipt, assuming no prior authorization delay. Mail-order specialty pharmacies shipping into Arizona typically require 2 to 5 business days from prescription verification to delivery [27].

When prior authorization is required, the process adds 3 to 14 business days. Expedited prior authorization reviews, which most major insurers are required to complete within 72 hours under Arizona insurance code, can shorten that window significantly [28]. Submitting the FSDS-DAO score, premenopausal documentation, and psychosocial evaluation note at the time of the initial PA request reduces back-and-forth and speeds approval [24].

503A compounding pharmacies in Arizona generally prepare orders within 3 to 7 business days from receipt of a valid prescription, depending on current compounding volume and API sourcing [26].

Transferring an Existing Vyleesi Prescription to Arizona

A patient who moves to Arizona or who has an existing prescription from an out-of-state provider can transfer it to an Arizona pharmacy, provided the original prescribing practitioner holds a current Arizona license or the prescription was issued while the patient was a resident of their previous state and the quantity dispensed does not exceed the original authorized amount [29]. Arizona pharmacy law does not restrict inter-state transfer of non-controlled substances as long as the prescribing practitioner's credentials can be verified [29].

Telehealth platforms licensed in multiple states can often re-issue a new prescription through an Arizona-licensed provider without requiring an entirely new intake, if medical records from the original prescriber are available for review [7]. Most HealthRX patients transferring from another state complete a 10-minute records-review appointment rather than a full initial intake.

Managing Side Effects: What Arizona Patients Should Know

Nausea is the most clinically significant adverse event. In RECONNECT, 40% of bremelanotide recipients reported nausea, and 13.2% rated it as severe [8]. The nausea typically peaks 30 to 60 minutes post-injection and resolves within 12 hours [4]. Pre-treating with ondansetron 4 mg orally 30 minutes before injection is an off-label but widely used strategy supported by clinical consensus, and Arizona telehealth prescribers can co-prescribe ondansetron on the same visit [11].

Flushing occurred in 20% of participants in RECONNECT and headache in 11% [8]. Both were transient. Focal hyperpigmentation of the face, gums, and breasts has been reported with repeated dosing in approximately 1% of patients in the open-label extension; this is a known on-target effect of melanocortin receptor activation and should be disclosed during informed consent [12].

Transient blood pressure elevation peaks at approximately 12 minutes post-injection and returns to baseline within 12 hours in most patients [4]. Women with a resting systolic blood pressure above 165 mmHg or diastolic above 100 mmHg should not use bremelanotide, per the FDA label [4]. Arizona telehealth prescribers should instruct patients to measure blood pressure 15 minutes after their first injection and report any reading above 160/100 mmHg before continuing use [20].

Cost Reduction Strategies Available in Arizona

The list price of branded Vyleesi is approximately $1,050 per auto-injector [21]. Several mechanisms exist to reduce this cost for Arizona patients.

The Palatin Technologies/AMAG co-pay card can reduce commercial insurance co-pays to $0 for eligible patients with qualifying coverage [23]. The patient assistance program offers the medication at no cost to uninsured patients meeting income criteria; applications are processed in approximately 5 to 10 business days [23].

GoodRx and similar discount programs list bremelanotide at select Arizona retail pharmacies for between $750 and $950 per dose, which represents a modest discount below list price [30]. The larger savings come from using a 503A compounding pharmacy when a legitimate medical rationale exists, where compounded bremelanotide 1.75 mg per dose may be available for $150 to $300 per dose depending on the pharmacy and formulation, though patients should confirm the pharmacy's Arizona Board of Pharmacy licensure and current compliance status before ordering [26].